Gemina Laboratories Ltd.
GLAB
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.94M | -2.51M | -2.74M | -3.22M | -3.87M |
| Total Depreciation and Amortization | 82.20K | 80.70K | 79.30K | 75.20K | 69.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 477.60K | 154.10K | 374.50K | 398.30K | 455.60K |
| Change in Net Operating Assets | 1.43M | 1.35M | 1.29M | 1.27M | 939.60K |
| Cash from Operations | -954.90K | -923.60K | -995.70K | -1.47M | -2.40M |
| Capital Expenditure | -- | 12.00K | 3.10K | -5.50K | -30.70K |
| Sale of Property, Plant, and Equipment | 13.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 13.00K | 12.00K | 3.10K | -5.50K | -30.70K |
| Total Debt Issued | 910.00K | 910.00K | 1.06M | 1.06M | 200.00K |
| Total Debt Repaid | -117.40K | -112.60K | -108.10K | -101.30K | -90.40K |
| Issuance of Common Stock | 518.40K | 516.80K | 516.80K | 0.00 | 3.20M |
| Repurchase of Common Stock | -1.60K | -1.60K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -27.20K | -33.30K | -27.20K | -27.20K | -111.40K |
| Cash from Financing | 942.50K | 939.40K | 1.06M | 686.10K | 2.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | -- | -- | -- |
| Net Change in Cash | 500.00 | 27.90K | 66.30K | -793.50K | -71.10K |